Evaluation of aminoglycoside and non-aminoglycoside compounds for stop-codon readthrough therapy in four lysosomal storage diseases

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Gómez Grau, Marta ^a   Garrido, Elena ^a,d   Cozar, Mónica ^a   Rodriguez Sureda, Víctor ^b   Domínguez, Carmen ^b   Arenas, Concepción ^a   Gatti, Richard A ^c   Cormand, Bru ^a   Grinberg, Daniel ^a   Vilageliu, Lluïsa ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIBIOTIC G 418; ATALUREN; BZ16; BZ6; COMPLEMENTARY DNA; GENTAMICIN; MESSENGER RNA; RTC13; RTC14; UNCLASSIFIED DRUG; STOP CODON;

ARTICLE; CONTROLLED STUDY; COS 1 CELL LINE; DRUG EFFICACY; ENZYME ACTIVITY; FIBROBLAST; GENE MUTATION; HUMAN; IN VITRO STUDY; LYSOSOME; LYSOSOME STORAGE DISEASE; MAROTEAUX LAMY SYNDROME; NIEMANN PICK DISEASE; NONSENSE MUTATION; SANFILIPPO A; SANFILIPPO B; SANFILIPPO C; SANFILIPPO SYNDROME; STOP CODON; TOXICITY; ANIMAL; CELL LINE; CHLOROCEBUS AETHIOPS; COS CELL LINE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; MUCOPOLYSACCHARIDOSIS III; MUCOPOLYSACCHARIDOSIS VI; NIEMANN-PICK DISEASE, TYPE A; NIEMANN-PICK DISEASE, TYPE B;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; CODON, NONSENSE; CODON, TERMINATOR; COS CELLS; FIBROBLASTS; GENTAMICINS; HUMANS; LYSOSOMES; MUCOPOLYSACCHARIDOSIS III; MUCOPOLYSACCHARIDOSIS VI; NIEMANN-PICK DISEASE, TYPE A; NIEMANN-PICK DISEASE, TYPE B; RNA, MESSENGER;

EID: 84942436633     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135873     Document Type: Article

References (59)

1. Boustany RM (2013) Lysosomal storage diseases - the horizon expands. Nat Rev Neurol 9:583-598. doi: 10.1038/nrneurol.2013.163 PMID: 23938739
2. Lee HL, Dougherty JP (2012) Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol Ther 136:227-266. doi: 10.1016/j.pharmthera.2012.07.007 PMID: 22820013
3. Keeling KM, Xue X, Gunn G, Bedwell DM (2014) Therapeutics based on stop codon readthrough. Annu Rev Genomics Hum Genet 15: 371-394. doi: 10.1146/annurev-genom-091212-153527 PMID: 24773318
4. Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, 8th edn, Vol. 3. New York: McGraw- Hill: 3421-3452.
5. Fan X, Zhang H, Zhang S, Bagshaw RD, Tropak MB, Callahan JW, et al. (2006) Identification of the gene encoding the enzyme deficient in mucopolysaccharidosis IIIC (Sanfilippo disease type C). Am J Hum Genet 79:738-744. PMID: 16960811
6. Hrebicek M, Mrazova L, Seyrantepe V, Durand S, Roslin NM, Nosková L, et al. (2006) Mutations in TMEM76∗ cause mucopolysaccharidosis IIIC (Sanfilippo C syndrome). Am J Hum Genet 79:807-819. PMID: 17033958
7. Klein U, Kresse H, von Figura K (1978) Sanfilippo syndrome type C: deficiency of acetyl-CoA:alpha-glucosaminide N-acetyltransferase in skin fibroblasts. Proc Natl Acad Sci U S A 75:5185-5189. PMID: 33384
8. Schuchman EH and Desnick RJ (2001) Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, 8th edn, Vol. 3. New York: McGraw-Hill: 3589-3610.
9. Gatti RA (2012) SMRT compounds correct nonsense mutations in primary immunodeficiency and other genetic models. Ann N Y Acad Sci 1250:33-40. doi: 10.1111/j.1749-6632.2012.06467.x PMID: 22364446
10. Howard M, Frizzell RA, Bedwell DM (1996) Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 2:467-469. PMID: 8597960
11. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104:375-381. PMID: 10449429
12. Nudelman I, Glikin D, Smolkin B, Hainrichson M, Belakhov V, Baasov T (2010) Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 18:3735-3746. doi: 10.1016/j.bmc.2010.03.060 PMID: 20409719
13. Bidou L, Allamand V, Rousset JP, Namy O (2012) Sense from nonsense: therapies for premature stop codon diseases. Trends Mol Med 18:679-688. doi: 10.1016/j.molmed.2012.09.008 PMID: 23083810
14. Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM (2001) Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 10:291-299. PMID: 11159948
15. Hein LK, Bawden M, Muller VJ, Sillence D, Hopwood JJ, Brooks DA (2004) alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J Mol Biol 338:453-462. PMID: 15081804
16. Brooks DA, Muller VJ, Hopwood JJ (2006) Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol Med 12:367-373. PMID: 16798086
17. Wang D, Belakhov V, Kandasamy J, Baasov T, Li SC, Li YT, et al. (2012). The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Mol Genet Metab 105:116-125. doi:10.1016/j.ymgme.2011.10.005 PMID: 22056610
18. Bartolomeo R, Polishchuk EV, Volpi N, Polishchuk RS, Auricchio A (2013) Pharmacological readthrough of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI. J Inherit Metab Dis 36:363-371. doi: 10.1007/s10545-012-9521-y PMID: 22971959
19. Gunn G, Dai Y, Du M, Belakhov V, Kandasamy J, Schoeb TR, et al. (2014) Long-term nonsense suppression therapy moderates MPS I-H disease progression. Mol Genet Metab 111:374-381. doi: 10.1016/j.ymgme.2013.12.007 PMID: 24411223
20. Du M, Keeling KM, Fan L, Liu X, Kovacs T, Sorscher E, et al. (2006) Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J Mol Med (Berl) 84:573-582.
21. Mattis VB, Rai R, Wang J, Chang CW, Coady T, Lorson CL (2006) Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet 120:589-601. PMID: 16951947
22. Buck NE, Wood L, Hu R, Peters HL (2009) Stop codon read-through of a methylmalonic aciduria mutation. Mol Genet Metab 97:244-249. doi: 10.1016/j.ymgme.2009.04.004 PMID: 19427250
23. Du L, Damoiseaux R, Nahas S, Gao K, Hu H, Pollard JM, et al. (2009) Nonaminoglycoside compounds induce readthrough of nonsense mutations. J Exp Med 206:2285-2297. doi: 10.1084/jem.20081940 PMID: 19770270
24. Jung ME, Ku JM, Du L, Hu H, Gatti RA (2011) Synthesis and evaluation of compounds that induce readthrough of premature termination codons. Bioorg Med Chem Lett 21:5842-5848. doi: 10.1016/j.bmcl.2011.07.107 PMID: 21873052
25. Nudelman I, Rebibo-Sabbah A, Cherniavsky M, Belakhov V, Hainrichson M, Chen F, et al. (2009) Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 52:2836-2845. doi: 10.1021/jm801640k PMID: 19309154
26. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87-91. PMID: 17450125
27. Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM (2008) PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A 105:2064-2069. doi: 10.1073/pnas.0711795105 PMID: 18272502
28. Finkel RS (2010) Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 25:1158-1164. doi: 10.1177/0883073810371129 PMID: 20519671
29. Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K (2011) PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C. Hum Gene Ther 22:537-547. doi: 10.1089/hum.2010.067 PMID: 21235327
30. Tan L, Narayan SB, Chen J, Meyers GD, Bennett MJ (2011) PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation. J Inherit Metab Dis 34:443-447. doi: 10.1007/s10545-010-9265-5 PMID: 21253826
31. Dranchak PK, Di Pietro E, Snowden A, Oesch N, Braverman NE, Steinberg SJ, et al. (2011) Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations. J Cell Biochem 112:1250-1258. doi: 10.1002/jcb.22979 PMID: 21465523
32. Sanchez-Alcudia R, Perez B, Ugarte M, Desviat LR (2012) Feasibility of nonsense mutation read-through as a novel therapeutical approach in propionic acidemia. Hum Mutat 33:973-980. doi: 10.1002/humu.22047 PMID: 22334403
33. McElroy SP, Nomura T, Torrie LS, Warbrick E, Gartner U, Wood G, et al. (2013) A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol 11:e1001593. doi: 10.1371/journal.pbio.1001593 PMID: 23824517
34. Peltz SW, Morsy M, Welch EM, Jacobson A (2013) Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 64:407-425. doi: 10.1146/annurev-med-120611-144851 PMID: 23215857
35. Gregory-Evans CY,Wang X, Wasan KM, Zhao J, Metcalfe AL, Gregory-Evans K (2014) Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects. J Clin Invest 124:111-116. doi: 10.1172/JCI70462 PMID: 24355924
36. Howard MT, Shirts BH, Petros LM, Flanigan KM, Gesteland RF, Atkins JF (2000) Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol 48:164-169. PMID: 10939566
37. Manuvakhova M, Keeling K, Bedwell DM (2000) Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6:1044-1055. PMID: 10917599
38. Bidou L, Hatin I, Perez N, Allamand V, Panthier JJ, Rousset JP (2004) Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther 11:619-627. PMID: 14973546
39. Allamand V, Bidou L, Arakawa M, Floquet C, Shiozuka M, Paturneau-Jouas M, et al. (2008) Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes. J Gene Med 10:217-224. PMID: 18074402
40. Bellais S, Le Goff C, Dagoneau N, Munnich A, Cormier-Daire V (2010) In vitro readthrough of termination codons by gentamycin in the Stuve-Wiedemann Syndrome. Eur J Hum Genet 18:130-132. doi: 10.1038/ejhg.2009.122 PMID: 19603067
41. Garrido E, Chabas A, Coll MJ, Blanco M, Dominguez C, Grinberg D, et al. (2007) Identification of the molecular defects in Spanish and Argentinian mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) patients, including 9 novel mutations. Mol Genet Metab 92:122-130. PMID: 17643332
42. Coll MJ, Anton C, Chabas A (2001) Allelic heterogeneity in Spanish patients with Sanfilippo disease type B. Identification of eight new mutations. J Inherit Metab Dis 24:83-84. PMID: 11286389
43. Matalonga L, Arias A, Coll MJ, Garcia-Villoria J, Gort L, et al. (2014) Treatment effect of coenzyme Q and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease. J Inherit Metab Dis 37: 439-446. doi: 10.1007/s10545-013-9668-1 PMID: 24347096
44. Voskoboeva E, Krasnopol'skaia KD, Peters K, von Figura K (2000) Identification of mutations in the arylsulfatase B gene in Russian mucopolysaccharidosis type VI patients. Genetika 36:837-843. PMID: 10923267
45. Villani GR, Balzano N, Vitale D, Saviano M, Pavone V, Di Natale P (1999) Maroteaux-lamy syndrome: five novel mutations and their structural localization. Biochim Biophys Acta 1453:185-192. PMID: 10036316
46. Rodriguez-Pascau L, Gort L, Schuchman EH, Vilageliu L, Grinberg D, Chabás A (2009) Identification and characterization of SMPD1 mutations causing Niemann-Pick types A and B in Spanish patients. Hum Mutat 30:1117-1122. doi: 10.1002/humu.21018 PMID: 19405096
47. Schuchman EH (1995) Two new mutations in the acid sphingomyelinase gene causing type a Niemann-pick disease: N389T and R441X. Hum Mutat 6:352-354. PMID: 8680412
48. Ruijter GJ, Valstar MJ, van de Kamp JM, van der Helm RM, Durand S, van Diggelen OP, et al. (2008) Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab 93:104-111. PMID: 18024218
49. Ouesleti S, Brunel V, Ben Turkia H, Dranguet H, Miled A, Miladi N, et al. (2011) Molecular characterization of MPS IIIA, MPS IIIB and MPS IIIC in Tunisian patients. Clin Chim Acta 412:2326-2331. doi: 10.1016/j.cca.2011.08.032 PMID: 21910976
50. Matos L, Canals I, Dridi L, Choi Y, Prata M, et al. (2014) Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations. Orphanet J Rare Dis. 9:180. doi: 10.1186/s13023-014-0180-y PMID: 25491247
51. Garrido E, Cormand B, Hopwood JJ, Chabas A, Grinberg D, Vilageliu L (2008) Maroteaux-Lamy syndrome: functional characterization of pathogenic mutations and polymorphisms in the arylsulfatase B gene. Mol Genet Metab 94:305-312. doi: 10.1016/j.ymgme.2008.02.012 PMID: 18406185
52. Du L, Jung ME, Damoiseaux R, Completo G, Fike F, Ku JM, et al. (2013) A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene. Mol Ther 21:1653-1660. doi: 10.1038/mt.2013.150 PMID: 23774824
53. Kuschal C, Digiovanna JJ, Khan SG, Gatti RA, Kraemer KH (2013) Repair of UV photolesions in xeroderma pigmentosum group C cells induced by translational readthrough of premature termination codons. Proc Natl Acad Sci U S A 110:19483-19488. doi: 10.1073/pnas.1312088110 PMID: 24218596
54. de Winter JCF (2013) Using the Student t-test with extremely small sample sizes. Prac Assess Res Eval 18:1-12.
55. Bordeira-Carrico R, Pego AP, Santos M, Oliveira C (2012) Cancer syndromes and therapy by stopcodon readthrough. Trends Mol Med 18:667-678. doi: 10.1016/j.molmed.2012.09.004 PMID: 23044248
56. Lai CH, Chun HH, Nahas SA, Mitui M, Gamo KM, Du L, et al. (2004) Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A 101:15676-15681. PMID: 15498871
57. Floquet C, Deforges J, Rousset JP, Bidou L (2011) Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res 39:3350-3362. doi: 10.1093/nar/gkq1277 PMID: 21149266
58. Kayali R, Ku JM, Khitrov G, Jung ME, Prikhodko O, Bertoni C (2012) Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum Mol Genet 21:4007-4020. doi: 10.1093/hmg/dds223 PMID: 22692682
59. Floquet C, Hatin I, Rousset JP, Bidou L (2012) Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin. PLoS Genet 8: e1002608. doi:10.1371/journal.pgen.1002608 PMID: 22479203